APRIL 2021, vilnius, lithuania
CTL (Cellular Technology Ltd.) has been pioneering the ELISPOT technology for immune monitoring. For over a decade, CTL’s mission has been “Elevating ELISPOT to an Exact Science”. Serving over 2,000 clients from academia and industry worldwide, CTL offers unparalleled expertise in immune monitoring.
AgenTus Therapeutics is focused on the discovery, development, and commercialization of breakthrough “living drugs” to advance cures for cancer patients. AgenTus will employ naturally-derived and engineered receptors, specifically T Cell Receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to supercharge human immune effector cells to seek and destroy cancer. AgenTus will also aim to advance adoptive cell therapy formats which would enable off-the-shelf living drugs.
The mission of the Cure Cancer Now Foundation is to ultimately win the battle against cancer.
Cancer Immunology, Immunotherapy has the basic aim of keeping readers informed of the latest research results in the fields of oncology and immunology. CITIM Conference summary and Focus Research Reviews are published in CII.
CellGenix, a global manufacturing leader of GMP-grade raw materials for cell therapy, gene therapy and tissue-engineered products, was the first company to obtain a GMP manufacturing authorization for therapeutic cell processing in Europe.